Skip to main content
Caplight Logo









BioSyngen

BioSyngen

Private
SingaporeHealthcare & Life Scienceshttps://biosyngen.com

Last Round

Early Funding

Oct 20, 2021

Total Funding Raised

$43.5M

Company Overview

BioSyngen is a biotechnology company that develops first-in-class cell therapies, including CAR-T, TCR-T, and TILs, to treat solid tumors and other cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

cell and gene therapyCAR-T therapycancer immunotherapyT-cell therapyCGTsolid tumor treatmentTCR-T therapyTIL therapyTumor-Infiltrating Lymphocytesautologous cell therapyGMP manufacturingGood Manufacturing Practiceclinical-stage biotechEBV-positive cancersnasopharyngeal carcinomaautomated cell manufacturingantigen discoveryOrphan Drug Designation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioSyngen Comparables

Compare BioSyngen with similar companies based on industry and business-model similarity.

BioSyngen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TCRCure Biopharma
87%
Lion TCR
84%
SCG Cell Therapy
84%

BioSyngen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingOct 20, 2021

Key People

Founding team and executive leadership

Hao Shen

President & CEO

Executive Team

BioSyngen Investors

Notable investors and investment history

BioSyngen investors
InvestorRounds
Science City (Guangzhou) Investment Group Co., Ltd.Early Funding

Recent news

Latest coverage and updates

  • is_developingAug 27, 2026

    Biosyngen Pte. Ltd. is developing international medical platform focused on immune cell therapy for solid tumours.

BioSyngen Filings

Explore SEC and related filing metadata, where available.

BioSyngen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersSingapore
Employee Range15
Year Founded2016
Last FundingOct 20, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?